Extended Data Fig. 4: FNI9 mAb mediates activation of CDC, ADCC and ADCP.
From: A pan-influenza antibody inhibiting neuraminidase via receptor mimicry
a,d, CDC with a serial dilution of FNI9 (red) and anti-HA MEDI8852 (green) mAbs on MDCK-LN cells infected with H1N1 PR8 in the presence of guinea pig complement. b,e, ADCC with FNI9 (red) and anti-HA MEDI8852 (green) mAbs on A549 cells infected with H1N1 PR8 in the presence of freshly isolated human NK cells. c,f, ADCP with serial dilution of FNI9 mAb (red) using peripheral blood mononuclear cells (PBMCs as source of monocytes) as effector cells, and PKH67-labelled ExpiCHO cells expressing N2 NA as target cells. The y-axis indicates the percentage of monocytes double positive for CD14 and PKH67. For all assays FNI9-GRLR (red empty circle) is used as Fc-silent negative control and results are shown both as dose-response curves (a-c) and as area under the curve (AUC) (d-f). Results are representative of n = 1 (d, e) or n = 2 (f) biological replicates (black dots).
